Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Jones Trading

<< Previous

Bullboard Posts

Next >>

Comment by SPCEO1on Jul 17, 2023 2:31pm

147 Views

Post# 35544558

RE:Jones Trading

The analyst reduced his price target because he took endometrial cancer out of his model for now since THTX is focusing on ovcarian cancer. He acknowledged TNBC or even endometrial might be part of the future of THTX again but likelt through partnership. He increased his possibility of success for TH-1902 in ovarian to 20% from 15%.

muslix1 wrote:

DJ Theratechnologies Price Target Cut to $3.00/Share From $6.00 by JonesTrading

Ratings actions from Benzinga: https://www.benzinga.com/quote/THTX/analyst-ratings

(END) Dow Jones Newswires

July 17, 2023 11:29 ET (15:29 GMT)

but maintained BUY